Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures?

× No keyword cloud information.

9 in total

1. Opportunity costs and uncertainty in the economic evaluation of health care interventions.

Authors: P Sendi; A Gafni; S Birch
Journal: Health Econ Date: 2002-01 Impact factor: 3.046

2. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?

Authors: Andreas Laupacis
Journal: CMAJ Date: 2002-01-08 Impact factor: 8.262

3. Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems.

Authors: S Birch; A Gafni
Journal: J Health Econ Date: 1993-12 Impact factor: 3.883

Review 4. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?

Authors: S Birch; A Gafni
Journal: J Health Econ Date: 1992-10 Impact factor: 3.883

5. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.

Authors: A Laupacis; D Feeny; A S Detsky; P X Tugwell
Journal: CMAJ Date: 1992-02-15 Impact factor: 8.262

6. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem.

Authors: A Gafni; S Birch
Journal: CMAJ Date: 1993-03-15 Impact factor: 8.262

7. Cost-effectiveness analysis: are the outputs worth the inputs?

Authors: D Naylor
Journal: ACP J Club Date: 1996 Jan-Feb

8. Foundations of cost-effectiveness analysis for health and medical practices.

Authors: M C Weinstein; W B Stason
Journal: N Engl J Med Date: 1977-03-31 Impact factor: 91.245

9. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.

Authors: L M Elit; A Gafni; M N Levine
Journal: J Clin Oncol Date: 1997-02 Impact factor: 44.544

9 in total

8 in total

1. Should cost-effectiveness take the blame?

Authors: Maurice McGregor
Journal: CMAJ Date: 2003-06-10 Impact factor: 8.262

2. The HAART side of resource allocation.

Authors: Pedram Sendi; Amiram Gafni
Journal: CMAJ Date: 2003-07-22 Impact factor: 8.262

3. Determining optimal population rates of cardiac catheterization: a phantom alternative?

Authors: Madhu K Natarajan; Amiram Gafni; Salim Yusuf
Journal: CMAJ Date: 2005-07-05 Impact factor: 8.262

Review 4. Information created to evade reality (ICER): things we should not look to for answers.

Authors: Stephen Birch; Amiram Gafni
Journal: Pharmacoeconomics Date: 2006 Impact factor: 4.981

5. Building bridges between academic research and policy formulation: when costing less means costing more.

Authors: Amiram Gafni; Stephen Birch
Journal: Pharmacoeconomics Date: 2007 Impact factor: 4.981

Review 6. Estimation, power and sample size calculations for stochastic cost and effectiveness analysis.

Authors: S D Walter; Amiram Gafni; Stephen Birch
Journal: Pharmacoeconomics Date: 2007 Impact factor: 4.981

Review 7. Literature review on the structure and operation of Pharmacy and Therapeutics Committees.

Authors: Esther Durán-García; Bernardo Santos-Ramos; Francesc Puigventos-Latorre; Ana Ortega
Journal: Int J Clin Pharm Date: 2011-03-18

8. Ethics, economics and the regulation and adoption of new medical devices: case studies in pelvic floor surgery.

Authors: Sue Ross; Charles Weijer; Amiram Gafni; Ariel Ducey; Carmen Thompson; Rene Lafreniere
Journal: BMC Med Ethics Date: 2010-08-26 Impact factor: 2.652

8 in total